Education
About Us
Working with TipRanks
Follow Us
Cartesian Therapeutics, Inc. (RNAC)
NASDAQ:RNAC
Descartes-08
Antisynthetase Syndrome
Phase II
Not Yet Recruiting
Descartes-08 in Autoantibody Myositis
Jan 29, 2026
―
Descartes-15
Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Phase I
Active Not Recruiting
Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma
Feb 28, 2024
―
Descartes-25
Relapse Multiple Myeloma, Multiple Myeloma
Phase I
Terminated
Descartes-25 in Relapsed/Refractory Multiple Myeloma
Oct 19, 2021
―
Descartes 11
Multiple Myeloma
Phase II
Completed
Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Jun 15, 2020
―
Descartes-08
Myasthenia Gravis, Generalized
Phase II
Active Not Recruiting
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)
Oct 29, 2019
―
Cyclophosphamide, Fludarabine, Descartes-11
Multiple Myeloma
Phase I
Terminated
Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma
Jun 19, 2019
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Cartesian Therapeutics, Inc. (RNAC) have in its pipeline
RNAC is currently developing the following drugs: Descartes-08, Descartes-08, Decartes-08. These drug candidates are in various stages of clinical development as the company works toward FDA approval.